A5056920540- Cardiac Fibrosis and Remodeling
- Signaling Pathways in Disease
- Health, psychology, and well-being
- Genomics and Rare Diseases
- Pharmacogenetics and Drug Metabolism
- Viral Infectious Diseases and Gene Expression in Insects
- Viral Infections and Immunology Research
- Mental Health Treatment and Access
- Child and Adolescent Psychosocial and Emotional Development
- CRISPR and Genetic Engineering
- BRCA gene mutations in cancer
- Resilience and Mental Health
- Atherosclerosis and Cardiovascular Diseases
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Psychological Well-being and Life Satisfaction
- Cardiac Imaging and Diagnostics
- Drug Transport and Resistance Mechanisms
- Nuclear Receptors and Signaling
- Cardiovascular Function and Risk Factors
- Cancer-related molecular mechanisms research
- Cytokine Signaling Pathways and Interactions
University of Turku
2018-2023
Turku Centre for Computer Science
2022-2023
Åbo Akademi University
2022-2023
Institute for Molecular Medicine Finland
2018-2019
Finland University
2019
University of Helsinki
2019
Turku Centre for Biotechnology
2016
Abstract The growth factor Neuregulin‐1 (NRG‐1) regulates myocardial and is currently under clinical investigation as a treatment for heart failure. Here, we demonstrate in several vitro vivo models that STAT5b mediates NRG‐1/EBBB4‐stimulated cardiomyocyte growth. Genetic chemical disruption of the NRG‐1/ERBB4 pathway reduces activation transcription target genes Igf1 , Myc Cdkn1a murine cardiomyocytes. Loss Stat5b also ablates NRG‐1‐induced hypertrophy. Dynamin‐2 shown to control cell...
An essential strategy to increase coverage of psychosocial treatments globally is task shifting non-medical counsellors, but evidence on its effectiveness still scarce. This study evaluates the lay counselling among persons with psychological distress in a primary health care setting rural Nepal.A parallel randomized controlled trial Dang, Nepal (NCT03544450). Persons aged 16 and older attending General Health Questionnaire (GHQ-12) score 6 or more were (1:1) receive either (PSY) enhanced...
Receptor tyrosine kinases (RTK) are potential targets for the treatment of ischemic heart disease. The human RTK family consists 55 members, most which have not yet been characterized expression or activity in heart. gene was analyzed from samples representing healthy tissue, acute myocardial infarction cardiomyopathy. As an experimental model, pig with ischemia-reperfusion injury, caused by cardiopulmonary bypass, used, phosphorylation status RTKs assessed a phospho-RTK array. Expression...
Abstract The return of blood flow to ischemic heart after myocardial infarction causes ischemia–reperfusion injury. There is a clinical need for novel therapeutic targets treat Here we screened the treatment injury using combination shRNA and drug library analyses in HL-1 mouse cardiomyocytes subjected hypoxia reoxygenation. included lentiviral constructs targeting 4625 genes 689 chemical compounds approved by Food Drug Administration (FDA). Data were analyzed protein–protein interaction...
The genetic basis of variability in drug response is at the core pharmacogenomics (PGx) studies, aiming reducing adverse reaction (ADR), which have interethnic variability. This study used Kardiovize Brno 2030 random urban Czech sample population to analyze polymorphisms a wide spectrum genes coding for liver enzymes involved metabolism. We aimed correlating real life consumption with pharmacogenomic profile, and comparing these data SUPER-Finland Finnish PGx database. A total 250...
Abstract Background/Introduction Heart failure is a potentially lethal cardiac disorder. The genetic variants as well the molecular signaling pathways accounting for majority of heritability sporadic heart are unknown. Here, we screened novel associated with in Finnish population. A previously uncharacterized variant TRIM55 was selected further validation. Purpose To identify and characterize failure-associated variants. Methods were from FINRISK survey study data by National Institute...
The growth factor neuregulin-1 (NRG-1) regulates hypertrophic and hyperplastic myocardial is currently under clinical investigation as a treatment for heart failure. We have previously demonstrated that an isoform of the NRG-1 receptor ERBB4 (ERBB4 JM-b) expressed in cardiomyocytes selectively activation STAT5b. To explore role STAT5b NRG-1/EBBB4 mediated cardiomyocyte growth, several vitro vivo models were utilized. downregulation NRG-1/ERBB4 signaling consistently reduced transcription...